Finding markers to predict lung inflammation from immunotherapy
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study looks for signs in the blood that can tell if a lung cancer patient is developing a side effect called pneumonitis (lung inflammation) from checkpoint inhibitor treatment. It may help doctors catch and treat this side effect early.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with lung cancer
- You have received at least one dose of an immune checkpoint inhibitor drug
- You are willing to sign a consent form
- If you have symptoms like fever, cough, or trouble breathing, you may be in the group with suspected pneumonitis
- If you have no symptoms or chest scan signs of lung inflammation, you may be in the control group
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for early “predictive markers” to tell who is most likely to develop lung inflammation after standard treatment for non-small cell lung cancer. It may help clinicians spot problems sooner and tailor care, using additional monitoring during treatment.
This study looks at using blood and imaging markers to predict if patients with lung cancer who receive both immunotherapy and chest radiation will develop lung inflammation (called radiation lung injury). It may help doctors personalise care and reduce side effects.
This study looks for early signs of lung inflammation (pneumonia) that can be caused by cancer treatments. By collecting samples from your lungs and blood before and during treatment, researchers hope to find markers that predict who might get this side effect, so it can be caught and treated earlier.
This trial studies how well immune checkpoint medicines (with or without chemotherapy) work for lung cancer, and looks for biomarkers—tests that may help predict who benefits. It may help you access a structured treatment plan and additional response testing.
This study looks at whether certain glycoproteins in your blood can help predict how well immunotherapy works for advanced non-small cell lung cancer. You would give blood samples before and after starting an immune checkpoint inhibitor treatment.
This study looks at genetic (DNA) information to find a marker that can help predict whether immunotherapy will work for lung cancer. If you’ve already received an immune checkpoint inhibitor, your tumor/genetic data may be analyzed to look for clues that guide treatment.
Hear when a new Checkpoint Inhibitor-related Pneumonitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.